NCT03830203View on ClinicalTrials.gov

Comparative Study of BAT1806 to RoActemra® in Rheumatoid Arthritis Patients With Inadequate Response to Methotrexate

PHASE3CompletedINTERVENTIONAL
Enrollment

621

Participants

Timeline

Start Date

December 19, 2018

Primary Completion Date

January 5, 2021

Study Completion Date

January 5, 2021

Conditions
Rheumatoid Arthritis
Interventions
DRUG

BAT1806

8 mg/kg

DRUG

Actemra(EU-licensed)

8 mg/kg

Trial Locations (1)

100730

Peking Union Medical College Hospital, Beijing

Sponsors
All Listed Sponsors
lead

Bio-Thera Solutions

INDUSTRY